Last reviewed · How we verify
PRAX-222 - Initial Dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PRAX-222 - Initial Dose (PRAX-222 - Initial Dose) — Praxis Precision Medicines.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PRAX-222 - Initial Dose TARGET | PRAX-222 - Initial Dose | Praxis Precision Medicines | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PRAX-222 - Initial Dose CI watch — RSS
- PRAX-222 - Initial Dose CI watch — Atom
- PRAX-222 - Initial Dose CI watch — JSON
- PRAX-222 - Initial Dose alone — RSS
Cite this brief
Drug Landscape (2026). PRAX-222 - Initial Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/prax-222-initial-dose. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab